SURMOUNT (Follow-up) The study will assess the effect of tirzepatide at the maximum tolerated dose (10 mg or 15 mg QW) compared with placebo in people living with obesity Medicine Tirzepatide Population ASCVD Phase III Starting year 2022 Director of Study drs. M.J. Asselman (Cardioloog) Tiel, Rivierenland
